DnB Asset Management AS Sells 596 Shares of IQVIA Holdings Inc. (NYSE:IQV)

DnB Asset Management AS decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 0.4% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 165,539 shares of the medical research company’s stock after selling 596 shares during the period. DnB Asset Management AS owned 0.09% of IQVIA worth $37,208,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. FMR LLC grew its position in shares of IQVIA by 24.7% during the 1st quarter. FMR LLC now owns 5,620,968 shares of the medical research company’s stock worth $1,117,954,000 after buying an additional 1,111,803 shares in the last quarter. Geode Capital Management LLC grew its holdings in IQVIA by 2.2% during the 1st quarter. Geode Capital Management LLC now owns 3,804,161 shares of the medical research company’s stock worth $754,864,000 after acquiring an additional 81,501 shares in the last quarter. Lazard Asset Management LLC grew its holdings in IQVIA by 1.0% during the 4th quarter. Lazard Asset Management LLC now owns 2,844,533 shares of the medical research company’s stock worth $582,814,000 after acquiring an additional 29,537 shares in the last quarter. Longview Partners Guernsey LTD increased its position in IQVIA by 9.4% during the 1st quarter. Longview Partners Guernsey LTD now owns 2,707,910 shares of the medical research company’s stock valued at $538,576,000 after purchasing an additional 232,872 shares during the period. Finally, Amundi raised its holdings in shares of IQVIA by 0.6% in the 4th quarter. Amundi now owns 2,230,818 shares of the medical research company’s stock valued at $494,193,000 after purchasing an additional 13,947 shares in the last quarter. 86.82% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

IQVIA stock traded down $2.77 during mid-day trading on Thursday, reaching $213.83. 327,868 shares of the company traded hands, compared to its average volume of 1,007,601. The firm’s fifty day moving average is $220.31 and its two-hundred day moving average is $208.05. The company has a market capitalization of $39.16 billion, a price-to-earnings ratio of 37.28, a price-to-earnings-growth ratio of 2.22 and a beta of 1.37. IQVIA Holdings Inc. has a fifty-two week low of $165.75 and a fifty-two week high of $241.86. The company has a debt-to-equity ratio of 2.16, a current ratio of 0.81 and a quick ratio of 0.81.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, August 1st. The medical research company reported $2.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.09 by $0.13. The firm had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.70 billion. IQVIA had a return on equity of 30.14% and a net margin of 7.47%. On average, equities research analysts expect that IQVIA Holdings Inc. will post 9.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the topic of several research reports. Morgan Stanley lifted their price objective on shares of IQVIA from $220.00 to $240.00 and gave the company an “overweight” rating in a report on Wednesday, August 2nd. Citigroup lifted their price target on IQVIA from $200.00 to $225.00 and gave the company a “neutral” rating in a report on Wednesday, August 2nd. HSBC began coverage on IQVIA in a research note on Wednesday, September 6th. They set a “buy” rating and a $260.00 price objective for the company. Truist Financial boosted their target price on shares of IQVIA from $244.00 to $260.00 and gave the stock a “buy” rating in a report on Tuesday, July 18th. Finally, StockNews.com started coverage on shares of IQVIA in a report on Thursday, August 17th. They issued a “hold” rating on the stock. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $252.00.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.